Tsubota Laboratory Incorporated

Tsubota Lab announced on the 7th that it has concluded a joint research agreement with Farstoma for the development of eye drops using ultrafine bubble (UFB) water, and its stock price rebounded. Farstoma has been advancing research on applying the characteristics of high-concentration UFB water to drug delivery systems for pharmaceuticals. This time, combining it with Tsubota Lab's expertise in the ophthalmology field, they will verify the applicability of UFB water to eye drops. Based on the findings obtained, they plan to consider the development of new pharmaceuticals in the ophthalmology field.

Mitsui Matsushima Holdings has revised upward its consolidated earnings forecast for the fiscal year ending March 2027 and announced an increase in its annual dividend. At the same time, it will make Sanyo, a manufacturer and seller of cotton swabs and cotton balls, a subsidiary. Separately, OBC reported a sharp profit increase for the first quarter of the fiscal year ending March 2027, while CDS and Toho Remac revised downward their consolidated earnings forecasts for the cumulative second quarter of the fiscal year ending December 2026. Bronco Billy announced its financial results and revised its earnings and dividend forecasts, and Stemrim reported that a patent for its regenerative medicine Redasemtide related to cartilage disease has been registered in Mexico. Tsubota Laboratory achieved a milestone upon submission of the clinical study report for TLG-001, confirming receipt of payment, Mitra established a wholly owned subsidiary specializing in inheritance-related services, and AZC Maruwa introduced a new shareholder benefit program.